Sort
261,768 grants matching “gene therapy”
CANCER AND INFLAMMATION: FUNCTION AND THERAPY
$879,352Michael Dean · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
$879,333Darell D Bigner · Duke University · R35 · FY2019 · CA
Studies of Human T Regulatory Cells
$879,282Ethan Shevach · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Rapid detection of pathogens and antimicrobial susceptibility directly in patient samples
$879,278Sadanand Gite · First Light Diagnostics , Inc. · R01 · FY2017 · AI
Role of autoreactivity in pathogenesis of chronic graft versus host disease
$879,263Defu Zeng · Beckman Research Institute/City Of Hope · R01 · FY2024 · HL
Role of autoreactivity in pathogenesis of chronic graft versus host disease
$879,263Defu Zeng · Beckman Research Institute/City Of Hope · R01 · FY2025 · HL
Role Of Monocytes In AIDS And As Targets For Antiviral Therapy
$879,248Sharon M Wahl · National Institute Of Dental & Craniofacial Research · ZIA · FY2009 · DE
Outcome Modifying Genes in Sickle Cell Disease
$879,236Duke University · R01 · FY2003 · HL
Systematic Investigation of Protein Ubiquitination in ARDS
$879,209Beibei Chen · University Of Pittsburgh At Pittsburgh · R35 · FY2020 · HL
Clinical Cancer Cytogenetics
$879,019Diane C Arthur · Division Of Basic Sciences - Nci · ZID · FY2016 · CA
I/O Tags: Genetically Encoded Tags for Trans-Neuronal Control Across Specific Synapse Classes
$878,991Michael Roland Williams · Henry Ford Health + Michigan State University Health Sciences · R01 · FY2025 · NS
UCLA Imaging Resource for Mouse Cancer Models
$878,929University Of California Los Angeles · R24 · FY2002 · CA
Rational Integration of Polygenic Risk Scores (RIPS)
$878,824Josh F. Peterson · Vanderbilt University Medical Center · R01 · FY2025 · HG
Preventing GVHD by inhibition of alloantigen presentation in the gut
$878,801Geoffrey Roger Hill · Fred Hutchinson Cancer Center · R01 · FY2025 · HL
HHSN26120120003 II CLINICAL STUDY OF THE EFFECT OF COMBINED TREATMENT OF ASPIRIN AND ZILEUTON ON BIOMARKERS OF TOBACCO-RELATED CARCINOGENESIS IN CURRENT CMOKERS 08/01/2014 - 07/31/2016
$878,749Sherry Chow · · N01 · FY2014 · CA
Clinical Pharmacogenetics
$878,724William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination
$878,617John Ross Teijaro · Scripps Research Institute, The · R01 · FY2023 · AI
Systems biology of HIV, methamphetamine and antiretrovirals interactions
$878,554Pietro P Sanna · Scripps Research Institute, The · R01 · FY2018 · DA
Mouse Models for Human Prostate Cancer
$878,546Charles L Sawyers · Sloan-Kettering Inst Can Research · U01 · FY2008 · CA
Development of an inhibitory oligonucleotide for the treatment of lupus
$878,519Robert L Coffman · Dynavax Technologies Corporation · R44 · FY2008 · AI
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL
$878,498Lindsey Ingerman James · Univ Of North Carolina Chapel Hill · R33 · FY2023 · DA
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL
$878,498Lindsey Ingerman James · Univ Of North Carolina Chapel Hill · R33 · FY2022 · DA
A therapeutic vaccine for chronic hepatitis B
$878,409David R. Milich · Vlp Biotech, Inc. · R44 · FY2019 · AI
Structure and function of eukaryotic DNA transposases
$878,398Frederick Dyda · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma
$878,390Kathryn Anne Defea · Parmedics, Inc. · R44 · FY2024 · HL